News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Argos Therapeutics, Inc. (ARGS) Release: Treatment With AGS-003 And Sunitinib Associated With Doubling Of Expected Survival In Patients With Unfavorable Risk Metastatic Renal Cell Carcinoma (mRCC)



6/2/2014 9:19:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DURHAM, N.C., June 2, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced updated results from a completed phase 2 study highlighting the long-term survival observed in patients treated with sunitinib combined with AGS-003, the company's investigational fully personalized immunotherapy for cancer. Results were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, May 30, 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES